Loblolly Pine Allergy Shots: America's Most-Planted Tree Myth-Buster
Loblolly pine (Pinus taeda) is the most commercially important timber tree in the US, covering 54 million acres of the Piedmont from the Carolinas to eastern Texas — and dumping huge pollen loads in February–April. Yet Bucholtz 1985 found only 3.2% of pollen-sensitive patients test positive to Pinus.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Loblolly Pineis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Loblolly Pine Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to loblolly pine — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of loblolly pine allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of loblolly pine immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of loblolly pine extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for loblolly pine allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing loblolly pine extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription loblolly pine immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat loblolly pine allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Loblolly Pine?
The biology, taxonomy, and clinical fingerprint of Loblolly Pine — the foundation of how SCIT targets it.
Loblolly pine (Pinus taeda) is the most economically important US softwood, producing dense pollen clouds in February–April across the Piedmont — yet only 3.2% of pollen-sensitive patients test positive to Pinus in unselected cohorts.
- Scientific name
- Pinus taeda
- Family
- PinaceaePine family
- Type
- Conifer plantation tree pollen
- Native to
- Piedmont and coastal plain of the southeastern US — New Jersey south to Florida, west to eastern Texas; now planted across ~54 million acres
- Allergen proteins
- No IUIS-named allergen registered for Pinus taeda; IgE-binding bands at 42 kDa and 6–8 kDa shared across Pinus genus (Gastaminza 2009)
- Particle size
- 60–80 μm (saccate, two air sacs)
- Avoidance difficulty
- Very difficult
How Loblolly Pine Allergy Presents
Symptoms by body system — useful for distinguishing Loblolly Pine sensitivity from overlapping allergies and infections.
Respiratory
- Nasal congestion and sneezing during February–April Piedmont pollen events
- Runny nose coinciding with dense pollen clouds across the loblolly belt
- Mild asthma exacerbation in confirmed Pinus-sensitized individuals
- Symptom overlap with concurrent shagbark hickory, white oak, and red maple — common misattribution to pine
Ocular
- Itchy, watery eyes during peak February–April Piedmont exposure
- Conjunctival redness after prolonged outdoor exposure in loblolly plantation areas
- Mild periorbital swelling in sensitized individuals
Dermal
- Contact urticaria from direct pollen exposure in plantation settings (uncommon)
- Pine resin contact dermatitis in forestry workers — distinct from IgE-mediated pollen allergy
- Mild hives in patients with documented Pinus sensitization after high-exposure outdoor events
Systemic
- Fatigue from disrupted sleep during the early spring Piedmont pollen season
- Reduced outdoor work capacity during February–April peak, especially in forestry and agricultural communities
- Symptom misattribution — shagbark hickory peaks almost simultaneously with loblolly in late March
In the Carolinas, loblolly pollen and shagbark hickory pollen peak almost on top of each other. If a patient comes in for pine allergy in late March, I test the full spring tree panel before writing the SCIT prescription — because the wrong shot for three years helps nobody.
When & Where Loblolly Pine Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late February through April in the Piedmont; Charlotte and Raleigh NAB stations log counts exceeding 2,500 grains/m³ in late March· Earlier and longer season than northern pines — begins in February in the Carolinas, up to 10 weeks total
US Exposure Map
6 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Moderate
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- High
- MD:
- Moderate
- DE:
- Moderate
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- High
- TN:
- Moderate
- NC:
- High
- SC:
- High
- OK:
- Moderate
- LA:
- Moderate
- MS:
- Moderate
- AL:
- Moderate
- GA:
- High
- TX:
- High
- FL:
- Moderate
- AK:
- Low
- HI:
- Low
What Loblolly Pine Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Loblolly pine shares near-complete IgE cross-reactivity with all Pinus species; it does not cross-react with Cupressaceae conifers, an important distinction for Piedmont patients who may simultaneously see cedar or juniper on their allergen panel.
Is SCIT Right for Your Loblolly Pine Allergy?
Answer five questions to assess whether loblolly pine allergy shots are the right immunotherapy target for your Piedmont spring symptoms.
How severe are your spring pollen symptoms during February–April in Piedmont states?
The Loblolly Pine SCIT Protocol
Loblolly pine SCIT follows the standard inhalant build-up schedule using a non-standardized extract; your allergist may include loblolly in a multi-species southeastern pine mix rather than a single-species vial.
Weekly injections escalate the loblolly pine extract over 16–24 weeks. Because loblolly season begins in February in the Carolinas, many allergists time SCIT initiation to autumn to complete build-up before the next pollen season. Traditionally a 30-minute observation period followed each injection in the clinic; with Curex, eligible patients self-administer the same escalation schedule at home, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand.
At-home self-injections with Curex, each followed by a 30-minute self-observation and any changes to a new vial or concentration supervised live in the Virtual Shot Room. Lot-to-lot variability in non-standardized pine extract may prompt dose adjustment when new vials are opened. Symptom diary review at 12 months assesses benefit.
After 3–5 years of maintenance, clinical response guides the discontinuation decision. No loblolly-specific endpoint data exist — the decision is based on symptom trajectory and shared discussion with your allergist.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Loblolly Pine SCIT
No randomized controlled trial exists for loblolly pine SCIT — the evidence base rests on pine pollen immunology studies and extrapolation from the inhalant SCIT class-level literature.
- Pinus sensitization in unselected pollen-allergic patients3%Bucholtz GA et al., J Allergy Clin Immunol, 1985, N=155
- IgE positivity in selected pine-allergic cohort69%Gastaminza G et al., Clin Exp Allergy, 2009, N=selected cohort
- Inhalant SCIT symptom reduction (class-level)60%Cox L et al., JACI, 2011 — AAAAI Practice Parameter meta-summary
No RCT has specifically evaluated loblolly pine SCIT. Pinus taeda accounts for approximately 80% of timber output in the 'loblolly belt' — its pollen visibility is extreme — but clinical sensitization remains low relative to pollen volume. Confirming pine-specific IgE is the mandatory first step before initiating any SCIT course.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Loblolly Pine SCIT Side Effects
Loblolly pine SCIT carries the standard inhalant SCIT side-effect profile, with lot-to-lot variability in non-standardized extracts warranting careful dose management when new vials arrive.
Local reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Most common; typically resolves within hours | Rate 30–50% | Mild |
Injection-site redness and itching More frequent at concentration step-ups during build-up | Rate 20–40% | Mild |
Large local reaction (>5 cm) Prompts dose reduction; not predictive of systemic reaction | Rate 5–15% | Moderate |
Systemic reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Generalized urticaria Requires epinephrine; with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector is confirmed on hand, with extended self-observation | Rate <1% | Moderate |
Rhinitis or conjunctivitis flare Temporary post-injection nasal or eye symptom exacerbation | Rate 1–3% | Mild |
Anaphylaxis 30-minute post-injection self-observation; with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand | Rate <0.01% per injection | Severe |
With Curex, pine serum is sterile-compounded to USP <797>, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector is confirmed on hand, and a 30-minute post-injection self-observation follows each dose. Proper protocol adherence makes systemic anaphylaxis from pine SCIT an extremely rare event.
SCIT vs Alternatives for Loblolly Pine
For Piedmont patients with confirmed loblolly pine sensitization, SCIT, sublingual drops, avoidance strategies, and daily medications are the main options.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate (no loblolly RCT; inhalant class extrapolation) | Emerging; no loblolly-specific trial | Limited — plantation pollen unavoidable | Symptomatic relief only |
| 5-yr cost | $3,500–$15,000 | Varies by provider; sold as a general sublingual modality, not Curex's product | Low | $500–$2,000/year |
| Duration | 3–5 years | 3–5 years | Ongoing | Indefinite |
| Convenience | At-home weekly self-injection with Curex during build-up; the first injection from each new vial or concentration supervised live in the Virtual Shot Room | Daily drops at home | HEPA filters; windows closed Feb–April | Daily pills/sprays |
| Safety | USP <797> serum; the first injection from each new vial or concentration supervised live in the Virtual Shot Room; prescribed epinephrine on hand; 30-min self-observation | Lower systemic reaction risk vs SCIT | Safe | Safe; antihistamine sedation risk |
| Lasting effect | Possible lasting tolerance | Possible lasting benefit | No immune modification | No lasting effect |
SCITBest
SLIT
Avoidance
Medications
For Piedmont patients who have confirmed loblolly pine sensitization, Curex now delivers SCIT as a weekly at-home injection with pricing confirmed in a current program quote — the serum is sterile-compounded to USP <797>, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a prescribed epinephrine auto-injector is confirmed on hand — so the 3–5 year course no longer requires in-office visits.
What Loblolly Pine SCIT Actually Costs
Most major insurers cover inhalant SCIT under standard allergy benefits when ordered by a board-certified allergist with documented pine sensitization. Loblolly extract is non-standardized; prior authorization may be required for some plans. Verify CPT 95165 extract preparation coverage before starting. Curex at-home IgE testing identifies specific loblolly pine sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your loblolly pine allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Loblolly Pine SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Loblolly pine (Pinus taeda) can begin releasing pollen as early as February in coastal North Carolina and the Piedmont, with peak counts in late March. NAB stations in Charlotte and Raleigh regularly log Pinus counts exceeding 2,500 grains/m³ in late March — among the highest pollen counts of the year. This early start is earlier than most northern pines and overlaps significantly with white oak and shagbark hickory seasons, making symptom attribution challenging without specific IgE testing.
Immunologically yes — loblolly pine (Pinus taeda) shares near-complete IgE cross-reactivity with all Pinus species, including white pine (P. strobus), ponderosa pine (P. ponderosa), and slash pine (P. elliottii), via shared IgE-binding bands at 42 kDa and 6–8 kDa (Gastaminza 2009). This is why most allergists prescribe a pine-mix vial rather than single-species loblolly. From a regulatory standpoint, no IUIS-named allergen has been registered for P. taeda, meaning all pine extracts are non-standardized regardless of species.
In the Piedmont, loblolly pine's February–April season overlaps significantly with white oak (Quercus alba), shagbark hickory (Carya ovata), and red maple (Acer rubrum) — all of which are far more common clinical sensitizers. Charlotte and Raleigh aerobiology calendars show concurrent peak days for pine, oak, and hickory in late March. A board-certified allergist can run a multi-tree panel that distinguishes loblolly pine sensitization from these overlapping species. This panel-first approach prevents the clinical scenario where patients receive 3 years of pine SCIT while hickory is the unaddressed primary sensitizer.
If your symptoms peak in February or early March before the loblolly pine count reaches maximum, you are likely reacting to red maple (Acer rubrum) — which is one of the earliest-blooming spring trees across the Piedmont, often releasing pollen before pine. If symptoms peak in late March, the concurrent shagbark hickory bloom is the most probable confounding source. Accurate timing of symptom peaks relative to the NAB pollen calendar is one of the inputs a board-certified allergist uses to narrow the allergen panel before ordering specific IgE tests.
Yes — antihistamines can be taken during loblolly pine SCIT and many allergists recommend taking one 30–60 minutes before each injection visit to reduce local reactions. Antihistamines do not interfere with the immunologic mechanism of SCIT. Because loblolly pollen season begins in February and the Piedmont spring allergy season can last 10+ weeks, patients often find daily antihistamine use necessary during peak exposure regardless of SCIT status. Always follow your specific allergist's protocol for antihistamine timing around injection visits.
Most major US health insurers cover subcutaneous immunotherapy under standard allergy benefits when ordered by a board-certified allergist with documented sensitization. Loblolly pine extract is non-standardized, so some NC and VA plans require prior authorization citing clinical necessity based on skin test or ImmunoCAP results. CPT codes 95115, 95117, and 95165 are standard across plans. The extract preparation code (95165) is the most variable for coverage — confirm this specifically with your insurer before starting. In-network allergist status also affects cost-sharing significantly.
AAAAI guidelines generally recommend initiating SCIT during the pre-season period — in the case of loblolly, this means starting in autumn (September–November) to complete most of the build-up phase before the February–April Piedmont season begins. Starting SCIT during peak pollen season increases the risk of systemic reactions and large local reactions because circulating IgE levels are elevated. Many Piedmont allergists schedule SCIT starts in autumn for loblolly-sensitized patients, allowing build-up to complete by February.
No — loblolly pine (Pinus taeda) and shagbark hickory (Carya ovata) are botanically unrelated with no cross-reactivity. Pine is Pinaceae; hickory is Juglandaceae. IgE antibodies raised against pine's 42 kDa and 6–8 kDa allergen bands do not bind hickory's allergens, and pine SCIT does not provide immunologic coverage for hickory. If testing reveals both pine and hickory sensitization, your allergist may prescribe a multi-allergen SCIT mixture covering both. Pursuing only pine SCIT when hickory is a significant sensitizer leaves a major gap in your immunotherapy coverage.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.